Cancer Vaccines - Global Strategic Business Report

The global market for Cancer Vaccines is estimated at US$7.9 Billion in 2023 and is projected to reach US$14.8 Billion by 2030, growing at a CAGR of 9.4% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

The growth in the cancer vaccine market is driven by several factors, including the increasing incidence of cancer worldwide, the rising demand for personalized medicine, and substantial investments in healthcare infrastructure supporting immunotherapy. As cancer remains a leading cause of death globally, governments and healthcare organizations are emphasizing early detection and prevention, which bolsters the market for preventive vaccines. In parallel, the therapeutic cancer vaccine sector benefits from the growing number of cancer patients who require effective treatment after diagnosis. Technological advancements in vaccine development platforms and adjuvant systems continue to enhance the efficacy and safety profiles of cancer vaccines, making them more appealing to both healthcare providers and patients. Additionally, the growing public awareness about the potential of immunotherapy in treating cancer, coupled with increasing healthcare spending in emerging economies, is propelling market growth. Market expansion is further supported by strategic collaborations between biopharmaceutical companies aiming to accelerate the development and commercialization of new vaccines. These drivers ensure the sustained growth of the cancer vaccine industry, reflecting its critical role in modern oncological therapeutics and preventive healthcare.

Key Insights:

• Market Growth: Understand the significant growth trajectory of the Preventive Vaccine segment, which is expected to reach US$7.6 Billion by 2030 with a CAGR of a 9.2%. The Therapeutic Vaccine segment is also set to grow at 10.1% CAGR over the analysis period.
• Regional Analysis: Gain insights into the U.S. market, estimated at $2.1 Billion in 2023, and China, forecasted to grow at an impressive 12.9% CAGR to reach $3.1 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

• Detailed Market Analysis: Access a thorough analysis of the Global Cancer Vaccines Market, covering all major geographic regions and market segments.
• Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
• Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Cancer Vaccines Market.
• Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

• How is the Global Cancer Vaccines Market expected to evolve by 2030?
• What are the main drivers and restraints affecting the market?
• Which market segments will grow the most over the forecast period?
• How will market shares for different regions and segments change by 2030?
• Who are the leading players in the market, and what are their prospects?

Report Features:

• Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
• In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
• Company Profiles: Coverage of major players such as Agenus Inc., Astellas Pharma Inc., AstraZeneca PLC, and more.
• Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Select Competitors (Total 61 Featured):

• Agenus Inc.
• Astellas Pharma Inc.
• AstraZeneca PLC
• Bristol-Myers Squibb Company
• Celldex Therapeutics Inc.
• F. Hoffmann-La Roche Ltd
• Genexine Inc.
• Gritstone bio
• ImmunityBio, Inc.
• Immutep Ltd
• ISA Pharmaceuticals B.V.
• Merck & Co. Inc.
• Northwest Biotherapeutics Inc.
• OncBioMune Pharmaceuticals Inc.
• Oncovir Inc.
• Pfizer Inc.
• Sanofi SA
• Serum Institute of India Pvt. Ltd.;